Cancel anytime
Alector Inc (ALEC)ALEC
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/29/2024: ALEC (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -72.7% | Upturn Advisory Performance 1 | Avg. Invested days: 19 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/29/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -72.7% | Avg. Invested days: 19 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/29/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 253.65M USD |
Price to earnings Ratio - | 1Y Target Price 10.28 |
Dividends yield (FY) - | Basic EPS (TTM) -1.71 |
Volume (30-day avg) 1136440 | Beta 0.66 |
52 Weeks Range 2.37 - 8.90 | Updated Date 12/1/2024 |
Company Size Small-Cap Stock | Market Capitalization 253.65M USD | Price to earnings Ratio - | 1Y Target Price 10.28 |
Dividends yield (FY) - | Basic EPS (TTM) -1.71 | Volume (30-day avg) 1136440 | Beta 0.66 |
52 Weeks Range 2.37 - 8.90 | Updated Date 12/1/2024 |
Earnings Date
Report Date 2024-11-05 | When BeforeMarket |
Estimate -0.53 | Actual -0.43 |
Report Date 2024-11-05 | When BeforeMarket | Estimate -0.53 | Actual -0.43 |
Profitability
Profit Margin -257.54% | Operating Margin (TTM) -301.32% |
Management Effectiveness
Return on Assets (TTM) -19.25% | Return on Equity (TTM) -112.55% |
Revenue by Products
Valuation
Trailing PE - | Forward PE 526.32 |
Enterprise Value -168917554 | Price to Sales(TTM) 4.12 |
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA -8.4 |
Shares Outstanding 97932600 | Shares Floating 82150766 |
Percent Insiders 10.08 | Percent Institutions 86.07 |
Trailing PE - | Forward PE 526.32 | Enterprise Value -168917554 | Price to Sales(TTM) 4.12 |
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA -8.4 | Shares Outstanding 97932600 | Shares Floating 82150766 |
Percent Insiders 10.08 | Percent Institutions 86.07 |
Analyst Ratings
Rating 4.18 | Target Price 13.78 | Buy 2 |
Strong Buy 6 | Hold 2 | Sell 1 |
Strong Sell - |
Rating 4.18 | Target Price 13.78 | Buy 2 | Strong Buy 6 |
Hold 2 | Sell 1 | Strong Sell - |
AI Summarization
Alector Inc. - Comprehensive Stock Analysis:
Company Profile:
History and Background: Alector, Inc., was founded in 2009. The company initially focused on developing therapies for neurodegenerative diseases such as Alzheimer's disease. However, in 2018, it shifted its focus to immuno-neurology, aiming to develop new drugs for inflammatory and neurodegenerative diseases of the central nervous system.
Core Business Areas: Alector currently focuses on three primary business areas:
- Immuno-neurology: Developing therapies for diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), caused by immune system dysfunction in the central nervous system.
- Neuroinflammation: Targeting neuroinflammation, a key contributor to various neurological conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis.
- Immune modulation: Modulating the immune system to treat diseases beyond the central nervous system.
Leadership and Corporate Structure: Alector has a diverse leadership team with expertise in drug development, neuroscience, and business management. Some key figures include:
- CEO and President: Arnon Rosenthal, Ph.D.: Leads the company with over two decades of experience in the pharmaceutical industry.
- Chief Scientific Officer: Christopher Proudfoot, Ph.D.: Oversees all research and development efforts with extensive experience in immunology and neuroscience.
- Chief Medical Officer: Michael Panzara, M.D.: Oversees all clinical development programs and has significant experience in clinical research and drug development.
Top Products and Market Share: Alector currently has no marketed products. However, their lead candidate, AL001, is under development for FTD and ALS. This is an anti-inflammatory monoclonal antibody targeting triggering receptor expressed on myeloid cells 2 (TREM2). AL001 is currently in Phase 3 clinical trials for FTD and Phase 2/3 trials for ALS.
Market Share Analysis: While Alector has no current market share due to no marketed products, the market for FTD treatments is estimated to reach $3 billion by 2025, while the ALS market is valued at around $3.5 billion in the same year. Alector faces competition from companies like Biogen and UCB, who also have drugs in development for these conditions.
Total Addressable Market (TAM): Alector's TAM is the total market for the diseases they aim to treat. This includes:
- FTD: Approximately 50,000 diagnosed cases in the US
- ALS: Estimated 30,000 diagnosed cases in the US
- Other Neuroinflammatory Conditions: This market is much larger, encompassing diseases like Alzheimer's, Parkinson's, and multiple sclerosis, with millions of patients worldwide.
Financial Performance: As of the most recent quarterly report, Alector reported:
- Revenue: $0 million
- Net Loss: $54.3 million
- Cash and Cash Equivalents: $445.4 million
- Cash Burn Rate: Approximately $35 million per quarter
Year-over-Year Performance: Alector's net loss has increased year-over-year, primarily due to rising research and development expenses. Cash burn rate also remains high due to clinical trial activities.
Dividends and Shareholder Returns: Alector does not currently pay dividends, as it is in the early stages of development and focused on investing in research and development. Total shareholder returns have been negative in recent years due to the company's pre-revenue status and lack of marketed products.
Growth Trajectory: Alector's future growth depends on the success of its clinical trials and the potential commercialization of its lead candidate, AL001. Positive results from clinical trials could lead to significant stock price appreciation, while regulatory setbacks or failures could have a negative impact.
Market Dynamics: The market for treatments of neurodegenerative and neuroinflammatory diseases is growing rapidly due to the aging population and increasing demand for new therapeutic options. However, this market is highly competitive, with many pharmaceutical and biotechnology companies vying for market share.
Continued below
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alector Inc
Exchange | NASDAQ | Headquaters | South San Francisco, CA, United States |
IPO Launch date | 2019-02-07 | Co-Founder, CEO & Director | Dr. Arnon Rosenthal Ph.D. |
Sector | Healthcare | Website | https://www.alector.com |
Industry | Biotechnology | Full time employees | 241 |
Headquaters | South San Francisco, CA, United States | ||
Co-Founder, CEO & Director | Dr. Arnon Rosenthal Ph.D. | ||
Website | https://www.alector.com | ||
Website | https://www.alector.com | ||
Full time employees | 241 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.